Tags: research + drugs.with.MS

Sort by: Date / Title / URL

1. Early Interferon Beta-1B (BetaseronR) In Multiple Sclerosis Patients Staves Off Disability
   "We have shown for the first time that immediate treatment after a first clinical demyelinating event suggestive of MS can reduce the early neurological damage, which may ultimately delay the development of the debilitating sequelae that characterize adv
   03-05-2007 to drugs, multiple sclerosis, newly diagnosed, relapsing remitting, research, rrms, study, treatment by admin
2. Reuters AlertNet - Rituxan shows promise in multiple sclerosis trial
   Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potentially more effective way of treating the progressive neurological disease.
   03-05-2007 to drug company, drugs, multiple sclerosis, research, rituxan, rrms, study by admin
3. Cannabis Based Medicine (Sativex®) Relieves Spasms And Stiffness In People With Multiple Sclerosis
   European Journal of Neurology (EJN) reports a study1 which shows that Sativex, a cannabis based medicine, significantly reduces intractable spasms and stiffness (spasticity) in people with Multiple Sclerosis
   05-03-2007 to drugs, marijuana, research, sativex, study, symptoms, uk by admin
4. Peptimmune Online - CO - 14
   The new peptides have been found to be more effective than Copaxone® in in-vitro and in-vivo assays, as well as in animal disease models of MS.
   17-02-2007 to copaxone, drug company, drugs, eae, multiple sclerosis, research, treatment by admin
5. Merck Serono Has Initiated The Onward Study To Evaluate Oral Cladribine As Add-On Treatment For Multiple Sclerosis - PipelineReview.com | Business Intelligence Center
   Merck Serono announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.
   07-02-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, rebif, research, treatment by admin
6. Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
   Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
   17-01-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, research, rrms, treatment by admin
7. RED HERRING | Cancer Curing Omelets?
   Researchers at the Roslin Institute in Edinburgh have genetically engineered chickens that could one day produce medicines to fight diseases like cancer and multiple sclerosis in their eggs.
   16-01-2007 to avonex, drugs, genetics, interferon, multiple sclerosis, rebif, research, treatment by admin
8. Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
   Serono announced today the initiation of a Phase III clinical trial to evaluate the effect of two dosage regimens of the new formulation of Rebif(R) (interferon beta-1a 44 mcg, three times a week or once a week) on the time to
   13-12-2006 to clinical trial, drug company, drugs, multiple sclerosis, rebif, relapsing remitting, research, rrms by admin
9. Roskamp Institute Looking for Volunteers for Multiple Sclerosis Research Study
   The Roskamp Institute announced today its participation in a pharmaceutical sponsored research study for relapsing-remitting Multiple Sclerosis (MS) sufferers.
   08-12-2006 to clinical trial, drug company, drugs, fingolimod, multiple sclerosis, relapsing remitting, research, rrms, study by admin
10. PharmaLive: CepTor Reports Significant Reduction of Multiple Sclerosis Symptoms with Oral Delivery of Neurodur in EAE Model
    The data indicated that the reduction of clinical symptoms of MS in EAE mice treated with oral Neurodur were statistically significant.
    13-10-2006 to drug company, drugs, eae, neurodur, research by admin
11. COPAXONE shows no increased risk during pregnancy
    Women who took COPAXONE® (glatiramer acetate injection) during part of their pregnancies demonstrated no more risk than the general population of pregnancy outcomes, according to an abstract presented this week at the American Academy of Neurology (AAN).
    06-10-2006 to copaxone, drugs, glatiramer acetate, multiple sclerosis, pregnancy, research, study, treatment by admin
12. Teva Says Copaxone Slows Tissue Damage - MSN Money
    Generic drug maker Teva Pharmaceutical Industries Ltd. said Monday new data from a study of its multiple sclerosis drug reinforce previous information that the treatment reduces relapses of symptoms and may slow tissue damage associated with the disease.
    03-10-2006 to copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin
13. News - Safety and Tolerability of Mitoxantrone for Worsening Multiple Sclerosis Appears Stable in Long Term
    Researchers report that the safety and tolerability of Novantrone (mitoxantrone) in long-term treatment of worsening multiple sclerosis appears to be consistent with its known safety profile.
    03-10-2006 to drugs, mitoxantrone, multiple sclerosis, ppms, research, study, treatment by admin
14. News - Glatiramer Acetate Shows Positive Impact on Average Relapse Rate and Disease Progression in Multiple Sclerosis For Up to 5 Years: Presented at ECTRIMS
    Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores.
    01-10-2006 to copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, pregnancy, relapsing remitting, research, rrms, study, treatment by admin
15. Tysabri Delays MS Relapse: Data
    A study of the drug's long-term effects estimated that patients on Tysabri would have an average of one relapse every 4.3 years.
    30-09-2006 to drug company, drugs, multiple sclerosis, relapsing remitting, research, tysabri by admin

First / Previous / Next / Last / Page 1 of 4